ReviewJournal of clinical medicine2015
Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics.
Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.Experimental dermatology · 2021Trial
- The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.The British journal of dermatology · 2019Trial
- Topical application of Jaungo in atopic dermatitis patients: study protocol for a randomized, controlled trial.Trials · 2017Trial
- Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.Experimental dermatology · 2017Trial
- Comparative Neuropsychiatric Outcomes of JAK Inhibitors, Dupilumab, and Conventional Immunosuppressants in Atopic Dermatitis: A Real-World Cohort Study.Biomedicines · 2026Article
- Lindera obtusiloba extract attenuates cytokine-mediated epidermal inflammation in keratinocytes and an MC903-induced AD-like mouse model.Scientific reports · 2026Article
- The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis.Biomedicines · 2026Review
- ATOJIN: A Natural Products Mixture, Alleviates Atopic Dermatitis in DNCB-Induced NC/Nga Mice.Mediators of inflammation · 2026Article
- Water Extract ofInternational journal of molecular sciences · 2025Article
- Atopic Dermatitis beyond Eczema: A Review on its Systemic Impact through Pruritus and Associated Comorbidities.Clinical reviews in allergy & immunology · 2025Review
- NFATc1 deficiency in B cells ameliorates atopic dermatitis.Scientific reports · 2025Article
- Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.Inflammopharmacology · 2025Review
- Integrative systems biology framework discovers common gene regulatory signatures in mechanistically distinct inflammatory skin diseases.NPJ systems biology and applications · 2025Article
- Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors.Journal of clinical medicine · 2025Article
- Comparative real-world effectiveness and safety of biologics and JAK inhibitors in atopic dermatitis: short- and medium-to-long-term analysis from a regional healthcare network in southern Spain.Frontiers in medicine · 2025Article
- Eczema: etiology, subtypes, therapeutic approaches and socioeconomic impact.Frontiers in allergy · 2025Review
- Impact of fucosyltransferase 1-mediated epidermal blood group antigen H on anti-inflammatory response in atopic dermatitis.Frontiers in immunology · 2024Article
- Anti-inflammatory and immunomodulatory effects of polysaccharide extracted from Wuguchong (maggot) on 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice.Frontiers in pharmacology · 2023Article
- Integrated bioinformatics-based identification of potential diagnostic biomarkers associated with atopic dermatitis.Postepy dermatologii i alergologii · 2022Article
- Atopic Dermatitis: Striving for Reliable Biomarkers.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is the most common inflammatory skin disease. Recent research findings have provided an insight into the complex pathogenic mechanisms involved in this disease. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are still lacking. Biomarkers of lesional, nonlesional skin, and blood have been developed for baseline as well as after treatment with broad and specific treatments (i.e., cyclosporine A and dupilumab). These biomarkers will help with the development of novel targeted therapeutics and assessment of disease reversal, with the promise of a more personalized treatment approach. Since AD involves more than one subtype (i.e., intrinsic/extrinsic, pediatric/adult, etc.), these molecular fingerprints needs to be validated in all subpopulations with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.